

**Zabrina Brumme, Ph.D.****Refereed papers published/in press**

1. Poon AFY, Swenson LC, Dong WWY, Deng W, Kosakovsky Pond S, **Brumme ZL**, Mullins JI, Richman DD, Harrigan PR, Frost SDW. Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. *Mol Biol Evol* 2009, in press.
2. **Brumme ZL**, Wang B, Nair K, Brumme CJ, De Pierres C, Reddy S, Julg B, Moodley E, Thobakgale C, Lu Z, van der Stok M, Bishop K, Mncube Z, Chonco F, Yuki Y, Frahm N, Brander C, Carrington M, Freedberg K, Kiepiela P, Goulder P, Walker B, Ndung'u, Losina E. Impact of select immunologic and virologic biomarkers on CD4 decline in chronic HIV-1 subtype C infection: Results from Sinikithemba longitudinal population-based cohort, Durban, South Africa. *Clin Infect Dis* 2009, Sep 15;49(6):956-64.
3. **Brumme ZL**, John M, Carlson M, Brumme CJ, Chan D, Brockman MA, Swenson L, Tao I, Szeto S, Rosato P, Sela J, Carl K, Frahm N, Brander C, Haas DW, Riddler S, Haubrich R, Walker BD, Harrigan PR, Heckerman D, Mallal S. HLA-associated immune escape pathways in Gag, Pol and Nef Proteins. *PLoS ONE* 2009, Aug 19;4(8):e6687.
4. Avila-Rios S, Ormsby CE, Carlson JM, Valenzuela-Ponce H, Blanco-Heredia J, Garrido-Rodriguez D, Garcia-Morales C, Heckerman D, **Brumme ZL**, Mallal S, John M, Espinosa E, Reyes-Teran G. Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. *Retrovirology*. 2009. Aug 10;6(1):72.
5. Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; **Nevirapine Toxicity Multicohort Collaboration**. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. *AIDS*. 2009 Aug 24; 23(13):1689-99.
6. **Brumme ZL, Walker BD**. Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification. *J Exp Med*. 2009; 206:1215-8.
7. **Antiretroviral Therapy Cohort Collaboration (ART-CC)**, Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. *Clin Infect Dis*. 2009 Apr 15;48(8):1138-51.
8. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, **Brumme Z**, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG, Klenerman P, Ndung'u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M,

- Goulder P. Adaptation of HIV-1 to human leukocyte antigen class I. *Nature*. 2009 Apr 2;458(7238):641-5.
9. Miura T, Brumme CJ, Brockman MA, **Brumme ZL**, Pereyra F, Block BL, Trocha A, John M, Mallal S, Harrigan PR, Walker BD. HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. *J Virol*. 2009 Apr;83(7):3407-12.
  10. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, **Brumme ZL**, Brumme CJ, Baker B, Rothchild AC, Li B, Trocha A, Cutrell E, Frahm N, Brander C, Toth I, Arts EJ, Allen TM, Walker BD. HLA-B57/B\*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. *J Virol*. 2009 Mar;83(6):2743-55.
  11. Schneidewind A, **Brumme ZL**, Brumme CJ, Power KA, Reyor LL, O'Sullivan K, Gladden A, Hempel U, Kuntzen T, Wang YE, Oniangue-Ndza C, Jessen H, Markowitz M, Rosenberg ES, Sékaly RP, Kelleher AD, Walker BD, Allen TM. Transmission and long-term stability of compensated CD8 escape mutations. *J Virol*. 2009 Apr;83(8):3993-7.
  12. Carlson JM, **Brumme ZL**, Rousseau CM, Brumme CJ, Matthews P, Kadie C, Mullins JI, Walker BD, Harrigan PR, Goulder PJ, Heckerman D. Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. *PLoS Comput Biol*. 2008 Nov;4(11):e1000225.
  13. Miura T, Brockman MA, **Brumme ZL**, Brumme CJ, Pereyra F, Trocha A, Block BL, Schneidewind A, Allen TM, Heckerman D, Walker BD. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. *J Virol*. 2009 Jan;83(1):140-9.
  14. **Brumme ZL\***, Brumme CJ\*, Carlson JM\*, Streeck H, John M, Eichbaum Q, Block BL, Baker B, Kadie C, Markowitz M, Jessen H, Kelleher AD, Rosenberg E, Kaldor J, Yuki Y, Carrington M, Allen TM, Mallal S, Altfeld M, Heckerman D, Walker BD. Marked epitope and allele-specific differences in rates of escape in HIV-1 Gag, Pol and Nef CTL epitopes in acute/early HIV-1 infection. *J Virol*. 2008 Sep;82(18):9216-27. (*note: \* denotes co-first author*)
  15. Miura T, Brockman MA, Brumme C, **Brumme ZL**, Carlson JM, Pereyra F, Trocha A, Addo MM, Block B, Rothchild A, Baker B, Flynn T, Schneidewind A, Li B, Wang Y, Heckerman D, Allen TM, Walker BD. Genetic characterization of Human Immunodeficiency Virus type 1 in elite controllers: Lack of gross genetic defects or common amino acid changes. *J Virol*. 2008 Sep;82(17):8422-30.
  16. **Brumme ZL**, Tao I, Szeto S, Brumme CJ, Carlson JM, Chan D, Kadie C, Frahm N, Brander C, Hogg RS, Walker BD, Heckerman D, Harrigan PR. CTL Escape mutations in HIV-1 Gag and their relationship with plasma viral load in chronic untreated infection. *AIDS* 2008, 22: 1277-1286.
  17. Streeck H, **Brumme ZL**, Anastario M, Cohen KW, Jolin KS, Meier A, Brumme CJ, Rosenberg ES, Alter G, Allen TM, Walker BD, Altfeld M. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T-cells. *PLoS Medicine* 2008, 5:e100.

18. Carlson JM and **Brumme ZL**. HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective. *Microbes Infect.* 2008; 10:455-61
19. Listgarten J, **Brumme Z**, Xiaojiang G, Walker B, Carrington M, Goulder P, Heckerman D. Statistical resolution of ambiguous HLA typing data. *PLoS Comput Biol.* 2008; 4:e1000016.
20. Low AJ, Marchant D, Brumme CJ, **Brumme ZL**, Dong W, Sing T, Hogg RS, Montaner JS, Gill V, Cheung PK, Harrigan PR. CD4-Dependent Characteristics of Coreceptor Use and HIV Type 1 V3 Sequence in a Large Population of Therapy-Naive Individuals. *AIDS Res Hum Retroviruses.* 2008; 24:219-28.
21. Harrigan PR, Mo T, Hirsch J, **Brumme ZL**, McKenna P, Bacheler L. A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy. *AIDS Res Hum Retroviruses* 2007; 23:895-9.
22. **Brumme ZL**, Brumme CJ, Heckerman D, Korber BT, Daniels M, Carlson J, Kadie C, Bhattacharya T, Chui C, Szinger J, Mo T, Hogg RS, Montaner JSG, Frahm N, Brander C, Walker BD, Harrigan PR. Evidence of differential HLA Class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. *PLoS Pathogens* 2007; 3:e94
23. Chui CKS\*, **Brumme ZL\***, Brumme CJ, Yip B, Phillips EJ, Montaner JSG, Harrigan PR. A simple screening approach to reduce B\*5701-associated abacavir hypersensitivity based on sequence variation in HIV reverse transcriptase. *Clin Infect Dis* 2007; 44:1503-8.  
(note: \* denotes co-first author)
24. **Brumme ZL\***, Brumme CJ\*, Chui C, Mo T, Wynhoven B, Woods CK, Hogg RS, Montaner JSG, Harrigan PR. Effects of HLA class I genetic parameters on clinical outcomes and survival after initiation of Highly Active Antiretroviral Therapy (HAART). *J Infect Dis* 2007;195:1694-704.  
(note: \* denotes co-first author)
25. Loutfy MR, Raboud JM, Montaner JS, Antoniou T, Wynhoven B, Smaill F, Rouleau D, Gill J, Schlech W, **Brumme ZL**, Mo T, Gough K, Rachlis A, Harrigan PR, Walmsley SL. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide. *Antiviral Res.* 2007; 75(1):58-63
26. **Brumme ZL**, Moyle G. The Epidemiology of HIV-1 coreceptor usage. *Journal of Viral Entry* 2006; 2:13-20.
27. **Brumme ZL**, Harrigan PR. The impact of human genetic variation on HIV disease in the era of HAART. *AIDS Rev* 2006; 8:78-87
28. Chui C, Cheung PK, Brumme CJ, Mo T, **Brumme ZL**, Montaner JS, Badley AD, Harrigan PR. HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. *AIDS Res Hum Retroviruses* 2006; 22:615-8.
29. Cote HCF, **Brumme ZL**, Chan JW, Guillemi S, Montaner JSG, and Harrigan PR. HIV therapy, HCV infection, antibiotics and obesity, a mitochondria killer mix? *AIDS* 2006; 20:1343-5.

30. **Brumme ZL**, Henrick BM, Brumme CJ, Hogg RS, Montaner JSG, and Harrigan PR. Association of CCR5 $\Delta$ 32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen. *Antivir Ther* 2005;10:849-53.
31. Toulson AR, Harrigan R, Heath K, Yip B, **Brumme ZL**, Harris M, Hogg RS, Montaner JS. Treatment Interruption of Highly Active Antiretroviral Therapy in Patients with Nadir CD4 Cell Counts >200 Cells/mm<sup>3</sup>. *J Infect Dis* 2005; 192:1787-93
32. **Brumme ZL**, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JSG, Harrigan PR. Molecular and Clinical Epidemiology of CXCR4-using HIV-1 in a large population of therapy-naïve individuals. *J Infect Dis* 2005;192:466-74.
33. Harrigan PR, Mo T, Wynhoven B, Hirsch J, **Brumme Z**, McKenna P, Pattery T, Vingerhoets J, Bachelier LT. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. *AIDS* 2005; 19:549-54.
34. Harrigan PR, Wynhoven B, **Brumme ZL**, Brumme CJ, Sattha B, Major JC, de la Rosa R, Montaner JSG. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. *J Infect Dis* 2005; 191:1325-30.
35. Harrigan PR, Hogg RS, Dong WYY, Yip B, Wynhoven B, Woodward J, Brumme CJ, **Brumme ZL**, Mo T, Alexander CS, Montaner JSG. Predictors of HIV drug resistance mutations in a large drug-naïve cohort initiating triple antiretroviral therapy. *J Infect Dis* 2005; 191: 339-47.
36. Recsky MA, **Brumme ZL**, Chan KJ, Wynhoven B, Yip B, Dong WWY, Heath KV, Montaner JSG, Levy AR, Hogg RS, Harrigan PR. Antiretroviral resistance among HIV-infected persons dying in British Columbia in the Era of Modern Antiretroviral Therapy. *J Infect Dis* 2004; 190:285-92.
37. **Brumme ZL**, Dong WW, Yip B, Wynhoven B, Hoffman NG, Swanstrom R, Jensen MA, Mullins JI, Hogg RS, Montaner JS, Harrigan PR. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. *AIDS* 2004; 18:F1-9.
38. Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, **Brumme ZL**, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. *Antivir Ther* 2003; 8:395-402.
39. Davani EY, **Brumme Z**, Singhera GK, Cote HC, Harrigan PR, Dorscheid DR. Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury. *Crit Care* 2003; 7:R176-83.
40. **Brumme ZL**, Chan KJ, Dong, W, Wynhoven B, Mo T, Hogg RS, Montaner JSG, O'Shaughnessy MV, Harrigan PR. Prevalence and clinical implications of insertions in the Human Immunodeficiency Virus Type-1 p6Gag N-terminal region in drug naive individuals initiating antiretroviral therapy. *Antivir Ther* 2003, 8:91-96.

41. **Brumme ZL**, Dong W, Chan KJ, Hogg R, Montaner JS, O'Shaughnessy MV, Harrigan PR. Influence of polymorphisms within the CX<sub>3</sub>CR1 and MDR-1 genes on initial treatment response in a large cohort initiating antiretroviral therapy. *AIDS* 2003, 17:201-208.
42. **Brumme ZL**, Chan KJ, Dong W, Mo T, Wynhoven B, Hogg RS, Montaner JSG, O'Shaughnessy MV, Harrigan PR. No association between GB Virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy. *AIDS* 2002, 16:1929-33
43. Harrigan PR, Salim M, Stammers DK, Wynhoven B, **Brumme ZL**, Mc Kenna P, Larder B, Kemp SD. A mutation in the 3' region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) is associated with non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) resistance. *J Virol* 2002, 76:6836-6840.
44. Harrigan PR, Miller MD, Mc Kenna P, **Brumme ZL**, Larder BA. Phenotypic Susceptibility of Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates. *Antimicrob Agents Chemother* 2002, 46:1067-1072
45. Cote HC, **Brumme ZL**, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JS. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. *N Engl J Med* 2002, 346:811-820.
46. **Brumme ZL**, Chan KJ, Dong W, Hogg R, O'Shaughnessy MV, Montaner JS, Harrigan PR. CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. *AIDS* 2001, 15:2259-2266.
47. Cote HC, **Brumme ZL**, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. *J Virol* 2001, 75:589-594.